Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45:309-16; PMID:18804401; http://dx.doi.org/10.1011/j.oraloncology.2008.06.002
   PubMed Web of Science ®Google Scholar
• Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009; 45:324-34; PMID:18805044; http://dx.doi.org/10.1011/j.oraloncology.2008.07.011
   PubMed Web of Science ®Google Scholar
• Pai SI. Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. Oncoimmunology 2013; 2:e24065; PMID:23762795; http://dx.doi.org/10.4166/onci.24065
   PubMedGoogle Scholar
• Serafini P, Weed DT. The immune system in head and neck squamous cell carcinoma: Interactions and therapeutic opportunities. Advances in Tumor Immunol Immunother 2014:275-321; http://dx.doi.org/10.1000/978-1-4614-8809-5_13
   Google Scholar
• Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ, Gutkind JS, Kulkarni AB, Sun ZJ. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma. Oncotarget 2015; 6(39):42067-80; PMID:26573233; http://dx.doi.org/10.18632/oncotarget.5955
   PubMed Web of Science ®Google Scholar
• Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A 2011; 108:12425-30; PMID:21746895; http://dx.doi.org/10.1077/pnas.1106645108
   PubMed Web of Science ®Google Scholar
• Qin H, Wei G, Gwak D, Dong Z, Xiong A, Kwak LW. Targeting tumor-associated myeloid cells for cancer immunotherapy. Oncoimmunology 2015; 4:e983961; PMID:25949898; http://dx.doi.org/10.4166/2162402X.2014.983761
   PubMedGoogle Scholar
• Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 2015; 4:e1016700; PMID:26140242; http://dx.doi.org/10.1088/2162402X.2015.1016700
   PubMed Web of Science ®Google Scholar
• Kida H, Ihara S, Kumanogoh A. Involvement of STAT3 in immune evasion during lung tumorigenesis. Oncoimmunology 2013; 2:e22653; PMID:23482587; http://dx.doi.org/10.4166/onci.22653
   PubMedGoogle Scholar
• Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14:736-46; PMID:25342631; http://dx.doi.org/10.1033/nrc3818
   PubMed Web of Science ®Google Scholar
• Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, Kroemer G. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. Cancer Res 2015; 75:3812-22; PMID:26208907; http://dx.doi.org/10.1155/0008-5472.CAN-15-1122
   PubMed Web of Science ®Google Scholar
• Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol 2011; 344:41-59; PMID:20517723; http://dx.doi.org/10.1007/82_2010_51
   PubMed Web of Science ®Google Scholar
• Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 2012; 18:5304-13; PMID:22859719; http://dx.doi.org/10.1155/1078-0432.CCR-12-1371
   PubMed Web of Science ®Google Scholar
• Hall B, Nakashima H, Sun ZJ, Sato Y, Bian Y, Husain SR, Puri RK, Kulkarni AB. Targeting of interleukin-13 receptor alpha2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling. J Transl Med 2013; 11:45; PMID:23421960; http://dx.doi.org/10.1188/1479-5876-11-45
   PubMed Web of Science ®Google Scholar
• Matozaki T, Murata Y, Okazawa H, Ohnishi H. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol 2009; 19:72-80; PMID:19144521; http://dx.doi.org/10.1011/j.tcb.2008.12.001
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Jr, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138:286-99; PMID:19632179; http://dx.doi.org/10.1011/j.cell.2009.05.045
   PubMed Web of Science ®Google Scholar
• Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8:806-23; PMID:19794444; http://dx.doi.org/10.1033/nrd2137
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1033/nrc3239
   PubMed Web of Science ®Google Scholar
• Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, Waes CV, Kulkarni AB. Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012; 31:3322-32; PMID:22037217; http://dx.doi.org/10.1033/onc.2011.494
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, Gabrilovich D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2003; 172:464-74; PMID:14688356; http://dx.doi.org/10.4044/jimmunol.172.1.464
   Web of Science ®Google Scholar
• Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, Blosser RL, Tam AJ, Bruno T, Zhang H et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013; 123:1580-9; PMID:23454751; http://dx.doi.org/10.1177/JCI60083
   PubMed Web of Science ®Google Scholar
• Wang H, Su X, Yang M, Chen T, Hou J, Li N, Cao X. Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma. Oncoimmunology 2015; 4:e1031440; PMID:26451302; http://dx.doi.org/10.1088/2162402X.2015.1031440
   PubMedGoogle Scholar
• Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 2007; 104:7391-6; PMID:17463090; http://dx.doi.org/10.1077/pnas.0609757104
   PubMed Web of Science ®Google Scholar
• Goswami KK, Barik S, Sarkar M, Bhowmick A, Biswas J, Bose A, Baral R. Targeting STAT3 phosphorylation by neem leaf glycoprotein prevents immune evasion exerted by supraglottic laryngeal tumor induced M2 macrophages. Mol Immunol 2014; 59:119-27; PMID:24607970; http://dx.doi.org/10.1011/j.molimm.2014.01.015
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51; PMID:17186030; http://dx.doi.org/10.1033/nri1995
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx.doi.org/10.1033/nrc2734
   PubMed Web of Science ®Google Scholar
• Zhang H, Nguyen-Jackson H, Panopoulos AD, Li HS, Murray PJ, Watowich SS. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 2010; 116:2462-71; PMID:20581311; http://dx.doi.org/10.1188/blood-2009-12-259630
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314-21; PMID:16288283; http://dx.doi.org/10.1033/nm1325
   PubMed Web of Science ®Google Scholar
• Zhang H, Neuhofer P, Song L, Rabe B, Lesina M, Kurkowski MU, Treiber M, Wartmann T, Regner S, Thorlacius H et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Invest 2013; 123:1019-31; PMID:23426178; http://dx.doi.org/10.1177/JCI64931
   PubMed Web of Science ®Google Scholar
• Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5:641-54; PMID:16056256; http://dx.doi.org/10.1033/nri1668
   PubMed Web of Science ®Google Scholar
• Maniecki MB, Etzerodt A, Ulhoi BP, Steiniche T, Borre M, Dyrskjot L, Orntoft TF, Moestrup SK, Moller HJ. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer 2012; 131:2320-31; PMID:22362417; http://dx.doi.org/10.1000/ijc.27506
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Takeya M, Komohara Y. A novel strategy for inducing the antitumor effects of triterpenoid compounds: blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition. Biomed Res Int 2014; 2014:348539; PMID:24738052; http://dx.doi.org/10.1155/2014/348539
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Ring AM, Schnorr PJ, Volkmer JP, Volkmer AK, Weissman IL, Garcia KC. Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPalpha variants. Oncoimmunology 2013; 2:e25773; PMID:24319639; http://dx.doi.org/10.4166/onci.25773
   PubMedGoogle Scholar
• Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, Jiang Z, Xu J, Liu Q, Cao X. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science 2014; 344:310-3; PMID:24744378; http://dx.doi.org/10.1122/science.1251456
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65:9525-35; PMID:16230418; http://dx.doi.org/10.1155/0008-5472.CAN-05-0529
   PubMed Web of Science ®Google Scholar
• Albesiano E, Davis M, See AP, Han JE, Lim M, Pardoll DM, Kim Y. Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma. Cancer Res 2010; 70:6467-76; PMID:20682796; http://dx.doi.org/10.1155/0008-5472.CAN-09-4058
   PubMed Web of Science ®Google Scholar
• Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, Kano A, Iwamoto Y, Li E, Craft JE et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 2003; 100:1879-84; PMID:12571365; http://dx.doi.org/10.1077/pnas.0237137100
   PubMed Web of Science ®Google Scholar
• Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54; PMID:14702634; http://dx.doi.org/10.1033/nm976
   PubMed Web of Science ®Google Scholar
• Kitamura H, Kamon H, Sawa S, Park SJ, Katunuma N, Ishihara K, Murakami M, Hirano T. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 2005; 23:491-502; PMID:16286017; http://dx.doi.org/10.1011/j.immuni.2005.09.010
   PubMed Web of Science ®Google Scholar
• Latour S, Tanaka H, Demeure C, Mateo V, Rubio M, Brown EJ, Maliszewski C, Lindberg FP, Oldenborg A, Ullrich A et al. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-α: downregulation of IL-12 responsiveness and inhibition of dendritic cell activation. J Immunol 2001; 167:2547-54; PMID:11509594; http://dx.doi.org/10.4044/jimmunol.167.5.2547
   PubMed Web of Science ®Google Scholar
• Zhang L, Sun ZJ, Bian Y, Kulkarni AB. MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma. Cancer Lett 2013; 331:230-8; PMID:23340180; http://dx.doi.org/10.1011/j.canlet.2013.01.003
   PubMed Web of Science ®Google Scholar
• Trellakis S, Bruderek K, Hutte J, Elian M, Hoffmann TK, Lang S, Brandau S. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun 2013; 19:328-36; PMID:23160385; http://dx.doi.org/10.1177/1753425912463618
   PubMed Web of Science ®Google Scholar
• Yu GT, Bu LL, Zhao YY, Liu B, Zhang WF, Zhao YF, Zhang L, Sun ZJ. Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. Am J Cancer Res 2014; 4:764-75; PMID:25520866
   PubMed Web of Science ®Google Scholar